¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼­¿ï¾Æ»êº´¿ø ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2019 Summer Workshop Cervical Cancer : 2019-08-11

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¼­¿ï¾Æ»êº´¿ø ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2019 Summer Workshop Cervical Cancer : 2019-08-11
±³À°ÀÏÀÚ : 2019-08-11
±³À°Àå¼Ò : ¼­¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ´ë°­´ç  
±³À°ÁÖÁ¦ : KGOG 2019 Summer Workshop Cervical Cancer
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸  
´ã´çÀÚ : KGOG
¿¬¶ôó : 02-512-5420  
À̸ÞÀÏ : koreagynonco@hanmail.net      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 15ºÐ  
¼¼ºÎ¼ö°­·á : 30,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 08:55~09:00 Orientation  ±è´ë¿¬(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 09:00~09:10 KGOG ÀڱðæºÎ¾Ï ÀÓ»ó½ÃÇè º¸°í  ±è´ë¿¬(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 09:10~09:20 NRG, GCIG ÀڱðæºÎ¾Ï ÀÓ»ó½ÃÇè º¸°í  ±è¹®È«(¿øÀÚ·ÂÀÇÇпø) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 09:20~09:40 2018 Revised FIGO staging: impact on clinical practice  ³ëÁÖ¿ø(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 09:40~10:00 The updates in early cervical cancer treatment  ÃÖöÈÆ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 10:00~10:20 The updates in locally advanced cervical cancer treatment  ¹é¹ÎÇö(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 10:20~10:40 The updates in recurrent, metastatic cervical cancer treatment  À̼ºÁ¾(°¡Å縯ÀÇ´ë) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 10:40~10:50 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 11:00~11:30 Current status of clinical trials in JGOG  TBD(Japan) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 11:30~11:50 Current status of translational research in JGOG  TBD(Japan) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 11:50~12:00 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 13:40~14:00 Current status of clinical trial using by BLS-ILB-E710c (HPV 16 E7 Ag-expressing L. casei vaccine) in patients with CIN 2/3.  ¼Û½ÂÈÆ(Â÷ÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 14:00~14:20 Clearance of persistent HPV infection and cervical lesion by GX-188E (therapeutic DNA vaccine) in CIN3 patients  (Genexine) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 14:20~14:40 Clinical trial tropical EGCG (Veregen¢ç) targeting cervical dysplasia and HPV infection: UWCCC Chemoprevention Consortium of US-NCI  ÀÌ¿µÀç(¿ï»êÀÇ´ë) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 14:40~14:50 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 15:10~15:30 Recent updates in cervical cancer immunotherapy  ¹Ú¿µÇÑ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 15:30~15:50 Real world experience of Pembrolizumab for cervical cancer patients  ÃÖ¹Îö(Â÷ÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 15:50~16:10 iRECIST: A clarification of tumour response assessment in the immunotherapy era  ±è°æ¿ø(¿ï»êÀÇ´ë) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:10~16:20 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:20~16:30 CX1902 Àç¹ß¼º, ÁøÇ༺, ÀüÀ̼º ÀڱðæºÎ¾Ï¿¡¼­ Ç×¾ÏÁ¦-¾Æ¹Ù½ºÆ¾ º´ÇÕ¿ä¹ýÀÇ ¾ÈÀü¼º ¹× È¿°úÆò°¡¸¦ À§ÇÑ ´Ù±â°ü ÈÄÇâÀû ÄÚȣƮ ±¸Ãà ¿¬±¸  ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:30~16:35 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:35~16:45 CX1903 MIS vs Open Surgery in Early cervical cancer Study (MOSES)  ¹ÚÁ¤¿­(¿ï»êÀÇ´ë) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:45~16:50 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:50~17:00 CX1904 Therapeutic effect of surgical debulking of metastatic lymph nodes in cervical cancer stage IIIC  ³ëÁÖ¿ø(µ¿±¹ÀÇ´ë) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 17:00~17:05 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 17:05~17:15 CX1905 Korean radical Tachelectomy of cerviX cancer assessment study (KTX)  ±èÁÖÇö(¿ï»êÀÇ´ë) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 17:15~17:20 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼­¿ï¾Æ»êº´¿ø ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2019 Summer Workshop Cervical Cancer : 2019-08-11""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Â÷ÀÇ°úÇдëÇб³ºÎ¼Ó±¸¹ÌÂ÷º´¿ø ½ÉÇ÷°ü¼¾ÅÍ ¿¬¼ö°­Á : 2019-08-16
´ÙÀ½±Û Á¦2ȸ ´ëÇÑ°©»ó¼±µÎ°æºÎ¿Ü°úÇÐȸ ÃÊÀ½ÆÄ¿öÅ©¼¥ : 2019-08-11
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
279 °­¿ø ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø Á¦ 130ȸ ¼ÒÈ­±â¼¾ÅÍ ¿¬¼ö±³À° : 2018-09-19 0 734 2018-07-28
278 ¼­¿ï Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ : 2018-09-19 0 502 2018-07-28
277 ¼­¿ï ¼ÛÆı¸(4Â÷) °³¿øÀÇ ¿¬¼ö±³À°(¿äÅëȯÀÚ, °ñ´Ù°øÁõ) : 2018-09-18 0 506 2018-07-28
276 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø ¾È°úÁö¿ªÀÇ»ç Áý´ãȸ : 2018-09-18 0 518 2018-07-28
275 °æ±â Â÷ÀÇ°úÇдëÇб³ºÐ´çÂ÷º´¿ø ³ì³»Àå : 2018-09-18 0 658 2018-07-28
274 ´ë±¸ ´ëÇѽŰæ°úÇÐȸ ´ë°æÁöȸ - ´ë°æ½Å°æ°úÀÇ»çȸ °øµ¿ ½ÉÆ÷Áö¿ò : 2018-09-18 0 1,497 2018-07-28
273 ¼­¿ï Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ : 2018-09-18 0 618 2018-07-28
272 ¼­¿ï Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ : 2018-09-17 0 424 2018-07-28
271 °æ±â Á¦ 1ȸ ¾ÆÁִ뺴¿ø ½ÅÀå³»°ú ¿¬¼ö°­Á : 2018-09-16 0 2,087 2018-07-28
270 ¼­¿ï ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Á¦53Â÷ ¾Ë·¹¸£±â ±³À°°­Á : 2018-09-16 0 568 2018-07-28
269 ¼­¿ï 2018³â Á¦3ȸ »ï¼º¼­¿ïº´¿ø ¿Ü°ú ½ÉÆ÷Áö¿ò : 2018-09-16 0 932 2018-07-28
268 ´ë±¸ 2018³âµµ ´ëÇÑÁ¤Çü¿Ü°úÀÇ»çȸ Çмú´ëȸ : 2018-09-16 0 821 2018-07-28
267 ¼­¿ï ½ÉÀå´ë»çÁõÈıº¿¬±¸È¸ 2018 Ãß°è½ÉÆ÷Áö¾ö : 2018-09-15 0 676 2018-07-28
266 ¼­¿ï °æÈñ´ëÇб³º´¿ø µ¿¹®Áý´ãȸ_°íȲÀ̺ñÀÎÈÄ°ú ¿¬±¸È¸ ¼¼¹Ì³ª : 2018-09-15 0 1,393 2018-07-28
265 ¼­¿ï 2018 Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ Á¤½ÅÄ¡·á Àü¹®°úÁ¤ : °æ°è¼± ÀΰÝÀå¾Ö : 2018-09-15 0 1,170 2018-07-28
1361 | 1362 | 1363 | 1364 | 1365 | 1366 | 1367 | 1368 | 1369 | 1370
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷